Clinical trial NCT04277832: Evaluating of New Screening Tool for Arthritis* in Psoriasis
Official title: Evaluation of a New Screening Tool (TUPAST) for Psoriatic Arthritis in Turkish Psoriasis Population and Comparison With TOPAS 2 for Validation of TUPAST
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psoriasis
Psoriatic Arthritis
Keywords: psoriasis
psoriatic arthritis
screening tool
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2020-02-20
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients over 18 years with psoriasis

Brief summary: This study evaluates a new screening tool for arthritis in psoriasis and compares its reliability with well-known screening tool (TOPAS 2).

Detailed description: Early diagnosis and treatment of PsA may prevent destruction in joints.Our aim is to create a simple and user friendly screening tool that can be used by dermatologists in out patient clinics.

A question pool will be created from a review of the literature and expert opinions from a physicians experienced in rheumatology and dermatologists .Psoriasis patients will answer these newly created questions. All patients will be examined by dermatology and also physical therapy and rehabilitation-rheumatology experts. The diagnosis of psoriatic arthritis (PsA) will be made by CASPAR (Classification criteria for psoriatic arthritis) criteria and ASAS (Assessment of Spondyloarthritis International Society) criteria for spondyloarthritis. Synchronously patients will be asked for to reply Turkish version of well known questionary named TOPAS 2. According to the results of collected data, statistically best matched questions will be selected for Turkish population. Also, the reliability of TUPAST (Turkish PsA Screening Tool) and TOPAS 2 (Toronto Psoriatic Arthritis Screen II) will be compared statistically.

Eligibility criteria: Inclusion Criteria:

* Psoriasis confirmed by dermatologist

Exclusion Criteria:

* Unable to consent and understand
* Known other rheumatological disease

Primary outcomes:
measure: Creation of new tool (TUPAST: Turkish psoriatic arthritis screening tool) for detecting psoriatic arthritis among psoriasis patients
timeFrame: six months, throughout the study
measure: Correlation between TOPAS 2 score and probability of psoriatic arthritis in psoriasis patients
timeFrame: six months, throughout the study
measure: Comparison of the reliability of the TUPAST and TOPAS 2
timeFrame: six months, throughout the study
measure: Correlation between TUPAST score and probability of psoriatic arthritis in psoriasis patients
timeFrame: six months, throughout the study
Secondary outcomes:
measure: Demographic characteristics demographic characteristics demographic characteristics
timeFrame: six months
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bezmialem Vakıf Univesity
Study officials:
affiliation: Bezmialem University
name: Nahide MD Onsun, Prof
role: STUDY_DIRECTOR
affiliation: Bezmialem University
name: Begüm MD Güneş
role: PRINCIPAL_INVESTIGATOR
References:
citation: Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007 Oct;57(4):581-7. doi: 10.1016/j.jaad.2007.04.001. Epub 2007 Jul 3.
citation: Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009 May-Jun;27(3):469-74.
citation: Chiowchanwisawakit P, Wattanamongkolsil L, Srinonprasert V, Petcharat C, Siriwanarangsun P, Katchamart W. Developing the Thai Siriraj Psoriatic Arthritis Screening Tool and validating the Thai Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire. Rheumatol Int. 2016 Oct;36(10):1459-68. doi: 10.1007/s00296-016-3513-4. Epub 2016 Jun 22.
citation: Audureau E, Roux F, Lons Danic D, Bagot M, Cantagrel A, Dernis E, Gouyette N, Hilliquin P, Jullien D, Liote F, Passeron T, A Richard M, Claudepierre P. Psoriatic arthritis screening by the dermatologist: development and first validation of the 'PURE-4 scale'. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1950-1953. doi: 10.1111/jdv.14861. Epub 2018 Mar 9.
citation: Duruoz MT, Sanal Toprak C, Ulutatar F. Validation of the Toronto Psoriatic Arthritis Screen II (TOPAS II) questionnaire in a Turkish population. Rheumatol Int. 2018 Feb;38(2):255-259. doi: 10.1007/s00296-017-3871-6. Epub 2017 Nov 7.